GMP scale up development has been completed for OCT1002 and OCT1004. The synthesis route has been re-designed for both assets to ensure ready supply of all necessary raw materials and in so doing the company has been able to cut manufacturing costs by 40% and reduce manufacturing processing time by 50%.

Final clinical drug formulations have been demonstrated for OCT1002 and OCT1004 together with maximum solubilities for both drugs.